TAIPEI, Aug. 25, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous...
Hence then, the article about senhwa completes enrollment in phase 1b cx 5461 expansion trial csr expected in q1 2027 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027 )
Also on site :
- Mary Janes Are ‘Timeless’ Fall Footwear, and This ‘Chic’ $30 Pair Is ‘Comfortable’ All Day With No Break-in Required
- Professional Chef Says These 3 ‘Old-Fashioned’ Meals from the 1940s Are the Definition of ‘Comfort Food’
- Ukraine hands Britain ‘goldmine’ of secret battlefield intelligence to protect bases from Russian spies